Jose Luis Pablos

Jose Luis Pablos

Auto-generated profile, based on publicly available information

Jose Luis Pablos

Department of Rheumatology, Instituto de Investigación Hospital 12 de Octubre, Complutense University of Madrid , Madrid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MMMario Mellado
Mario Mellado
LMLaura Martínez Muñoz
Laura Martínez Muñoz
GCGraciela Cascio
Graciela Cascio
PLPilar Lucas
Pilar Lucas
JPJosé L Pablos
José L Pablos
JRJosé Miguel Rodríguez-Frade
José Miguel Rodríguez-Frade
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation in joints, associated with synovial hyperplasia and with bone and cartilage destruction. Although the primacy of T cell-related events early in the disease continues to be debated, there is strong evidence that autoantigen recognition by specific T cells is crucial to the pathophysiology of rheumatoid synovitis. In addition, T cells are key components of the immune cell infiltrate detected in the joints of RA patients. Initial analysis of the cytokines released into the synovial membrane showed an imbalance, with a predominance of proinflammatory mediators, indicating a deleterious effect of Th1 T cells. There is nonetheless evidence that Th17 cells also play an important role in RA. T cells migrate from the bloodstream to the synovial tissue via their interactions with the endothelial cells that line synovial postcapillary venules. At this stage, selectins, integrins and chemokines have a central role in blood cell invasion of synovial tissue, and therefore in the intensity of the inflammatory response. In this review we will focus on the mechanisms involved in T cell attraction to the joint, the proteins involved in their extravasation from blood vessels, and the signaling pathways activated. Knowledge of these processes will lead to a better understanding of the mechanism by which the systemic immune response causes local joint disorders and will help to provide a molecular basis for therapeutic strategies.

1 December 2014 in Cell Host & Microbe
Verified
Journal Article
Open access
ABAmy E. Baxter
Amy E. Baxter
RRRebecca A. Russell
Rebecca A. Russell
CDChristopher J.A. Duncan
Christopher J.A. Duncan
MMMichael D. Moore
Michael D. Moore
CWChristian B. Willberg
Christian B. Willberg
QSQuentin Sattentau
Quentin Sattentau
Macrophages contribute to HIV-1 pathogenesis by forming a viral reservoir and mediating neurological disorders. Cell-free HIV-1 infection of macrophages is inefficient, in part due to low plasma membrane expression of viral entry receptors. We find that macrophages selectively capture and engulf HIV-1-infected CD4+ T cells leading to efficient macrophage infection. Infected T cells, both healthy and dead or dying, were taken up through viral envelope glycoprotein-receptor-independent interactions, implying a mechanism distinct from conventional virological synapse formation. Macrophages infected by this cell-to-cell route were highly permissive for both CCR5-using macrophage-tropic and otherwise weakly macrophage-tropic transmitted/founder viruses but restrictive for nonmacrophage-tropic CXCR4-using virus. These results have implications for establishment of the macrophage reservoir and HIV-1 dissemination in vivo.

1 December 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
JPJose L Pablos
Jose L Pablos
MGMaría Galindo
María Galindo
LCLoreto Carmona
Loreto Carmona
ALAna Lledó
Ana Lledó
MRMiriam Retuerto
Miriam Retuerto
AFAntonio Fernandez-Nebro
Antonio Fernandez-Nebro
Objectives The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with a matched control cohort to identify potential risk factors for severe illness. Methods In this comparative cohort study, we identified hospital PCR+COVID-19 rheumatic patients with chronic inflammatory arthritis (IA) or connective tissue diseases (CTDs). Non-rheumatic controls were randomly sampled 1:1 and matched by age, sex and PCR date. The main outcome was severe COVID-19, defined as death, invasive ventilation, intensive care unit admission or serious complications. We assessed the association between the outcome and the potential prognostic variables, adjusted by COVID-19 treatment, using logistic regression. Results The cohorts were composed of 456 rheumatic and non-rheumatic patients, in equal numbers. Mean age was 63 (IQR 53–78) years and male sex 41% in both cohorts. Rheumatic diseases were IA (60%) and CTD (40%). Most patients (74%) had been hospitalised, and the risk of severe COVID-19 was 31.6% in the rheumatic and 28.1% in the non-rheumatic cohort. Ageing, male sex and previous comorbidity (obesity, diabetes, hypertension, cardiovascular or lung disease) increased the risk in the rheumatic cohort by bivariate analysis. In logistic regression analysis, independent factors associated with severe COVID-19 were increased age (OR 4.83; 95% CI 2.78 to 8.36), male sex (1.93; CI 1.21 to 3.07) and having a CTD (OR 1.82; CI 1.00 to 3.30). Conclusion In hospitalised patients with chronic inflammatory rheumatic diseases, having a CTD but not IA nor previous immunosuppressive therapies was associated with severe COVID-19.

1 September 2005 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
BSBegoña Santiago
Begoña Santiago
Irene Gutiérrez-CañasIrene Gutiérrez-Cañas
Irene Gutiérrez-Cañas
JDJavier Dotor
Javier Dotor
GPGuillermo Palao
Guillermo Palao
JLJuan José Lasarte
Juan José Lasarte
JPJosé L. Pablos
José L. Pablos

16 October 2014 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
BSBlanca Soler
Blanca Soler
LELizbeth Estrada‐Capetillo
Lizbeth Estrada‐Capetillo
EIElena Izquierdo
Elena Izquierdo
GCGabriel Criado
Gabriel Criado
CNConcha Nieto
Concha Nieto
APAmaya Puig‐Kröger
Amaya Puig‐Kröger

15 February 2003 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JPJosé L Pablos
José L Pablos
BSBegoña Santiago
Begoña Santiago
MGMaría Galindo-Izquierdo
María Galindo-Izquierdo
CTCarmen Torres
Carmen Torres
MBMaría T Brehmer
María T Brehmer
FBFrancisco Blanco
Francisco Blanco
CXCL12 (stromal cell-derived factor-1) is a potent CXC chemokine that is constitutively expressed by stromal resident cells. Although it is considered a homeostatic rather than an inflammatory chemokine, CXCL12 has been immunodetected in different inflammatory diseases, but also in normal tissues, ant its potential functions and regulation in inflammation are not well known. In this study, we examined the cellular sources of CXCL12 gene expression and the mechanism and effects of its interactions with endothelial cells in rheumatoid arthritis synovium. We show that CXCL12 mRNA was not overexpressed nor induced in cultured rheumatoid synoviocytes, but it specifically accumulated in the rheumatoid hyperplastic lining layer and endothelium. CXCL12 gene expression was restricted to fibroblast-like synoviocytes, whereas endothelial cells did not express CXCL12 mRNA, but displayed the protein on heparitinase-sensitive factors. CXCL12 colocalized with the angiogenesis marker αvβ3 integrin in rheumatoid endothelium and induced angiogenesis in s.c. Matrigel plugs in mice. The angiogenic activity of rheumatoid synovial fluid in vivo was abrogated by specific immunodepletion of CXCL12. Our results indicate that synoviocyte-derived CXCL12 accumulates and it is immobilized on heparan sulfate molecules of endothelial cells, where it can promote angiogenesis and inflammatory cell infiltration, supporting a multifaceted function for this chemokine in the pathogenesis of rheumatoid arthritis.